A new treatment option for patients with advanced non-small-cell lung cancer (NSCLC) harboring a KRASG12C mutation is on the horizon.
Read MoreCase Report: 58-Year-Old Woman with Neuroendocrine Carcinoma of the Cervix
Next generation sequencing provides insights into more effective treatments for a patient’s rare cancer.
Global Trial Seeks New Gold Standard Treatment for HER2+ Early Breast Cancer in Post-Neoadjuvant Setting
A global, phase 3 clinical trial will investigate a novel drug in the post neoadjuvant setting that researchers hope will be a significant improvement over the current standard of care.
Case Report: 46-Year-Old with Metastatic Papillary Thyroid Cancer
A patient responds to selpercatinib after failing lenvatinib and presenting with COVID-19-like symptoms at the beginning of the global pandemic.
FDA Approves New Treatment Regime for Advanced Liver Cancer
In May, the FDA approved atezolizumab in combination with bevacizumab for newly diagnosed patients with hepatocellular carcinoma.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A New Option for Patients with RET Fusion-Positive NSCLC Demonstrates Safety and Efficacy
The selective RET inhibitor selpercatinib is safe and effective in both treated and treatment-naïve patients with RET fusion-positive NSCLC.
Rivaroxaban Reduces VTE in Patients with Pancreatic Cancer
A secondary analysis of the CASSINI trial finds that rivaroxaban is an effective thromboprophylactic for patients with pancreatic cancer receiving systemic therapy.
Metastatic Non-Clear Cell Renal Cancer Patients Have Positive Response to Immunotherapy
Despite major progress in treating metastatic clear cell renal cell carcinoma, metastatic non-clear cell renal cell carcinoma remains poorly understood.
Three Treatment Modalities Emerge for Patients with Triple-Negative Breast Cancer
A breast oncologist’s take on three new treatment modalities for a difficult-to-treat cancer.
More Therapies to Consider for Advanced and Refractory Renal Cell Carcinoma
Results of two trials add more potential paths to improved survival to the rapidly evolving landscape of RCC treatment.
KEYNOTE-426: Pembrolizumab + Axitinib or Sunitinib Alone for Advanced Renal Cell Carcinoma?
Staggering results in this phase 3 trial point to the future of care for advanced renal cell carcinoma.